Alexandria Venture Investments wins fifth consecutive year as the most active corporate investor in the biopharmaceutical industry

0

Alexandria is at the forefront and at the heart of the life science industry, identifying and investing wisely in highly disruptive cutting-edge companies that pursue transformational technologies and therapies to improve people’s lives and reduce cost. and the burden of disease

PASADENA, California, January 10, 2022 / PRNewswire / – Alexandria Venture Investments, the strategic venture capital platform of Alexandria Real Estate Equities, Inc. (NYSE: ARE), an urban office REIT and the oldest owner, operator and developer and the most pioneering uniquely focused life science, agtech and technology campus collaboration in AAA innovation hubs, today announced that it has been recognized by Silicon Valley Bank in its ” Healthcare Investments and Exits: Annual 2022 Report ”as the most active corporate investor in the biopharmaceutical sector in terms of new transaction volume (2020-2021) for the fifth consecutive year. This continued and important recognition is a testament to that of Alexandria high-impact leadership and collaboration in the vital life sciences industry, advancing transformative new modalities and platforms to significantly improve human health and reduce healthcare costs. Since its inception in 1996, Alexandria Venture Investments has made strategic investments in disruptive companies in the life sciences, agribusiness, climate change and technology. that of Alexandria a strong venture capital activity is an integral part of the unique and multifaceted activity of the company and provides valuable information on key industry trends and innovation; builds and strengthens relationships with key entrepreneurs and investors; and further strengthens its high-quality roster of over 800 innovative tenants.

“We are extremely proud to continue to be at the forefront and at the heart of the life sciences industry, which has delivered life-saving COVID-19 tests, vaccines and therapies in record time and now continues. to take advantage of its innovative platforms to extend the toolkit for the current course Combating Infectious Diseases, ”said Joel S. marcus, Executive Chairman and Founder of Alexandria Real Estate Equities, Inc. and Founder and Director of Alexandria Venture Investments. “With more than 10,000 diseases known to mankind and less than 10% currently treatable with therapy, our tenants and venture capitalists are working tirelessly to successfully meet this huge unmet medical need. This essential innovation is also the most effective way to scale down and manage healthcare. We are in the early days of the golden age of biology, accelerated by an exciting convergence of biology and technology, and we are more than ever determined to partner with pioneering companies ready to dramatically improve the future of human health. “

Alexandria Venture Investments has a decades-long track record of investing in dynamic companies that develop drugs that change and save lives while generating strong and consistent financial returns. From December 31, 2021, the strong platform experience has enabled Alexandria Venture Investments to generate realized and unrealized returns of over 10x for numerous portfolio companies working on new infectious disease, neuroscience, oncology and drug platforms. generation. Building on this historic success, Alexandria continues to invest in impactful companies that advance discovery in a range of key areas, including infectious diseases and neuroscience, as well as in breakthrough platforms with immense potential to fight a wide range of diseases.

About Alexandria Real Estate Equities, Inc.

Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® urban office REIT, is the oldest and most pioneering owner, operator and developer, focused solely on collaborative life sciences, agtech and technology campuses in AAA innovation hubs, with a total market capitalization of $ 38.6 billion as of September 30, 2021 and an asset base in North America of SF 63.9 million. The asset base in North America includes 38.7 million RSF from properties in operation and 4.3 million RSF from Category A properties under construction, 8.9 million RSF from short and medium term development and redevelopment projects and 12.0 million SF of future development projects. Founded in 1994, Alexandria pioneer of this niche and has since established a significant market presence in key locations including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland and Research Triangle. Alexandria has a long-standing and proven track record of developing Class A properties clustered in urban life science, agtech and tech campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity and success. Alexandria also provides strategic capital to transformative life sciences, agtech and technology companies through our venture capital platform. We believe that our unique business model and diligent underwriting ensures a high quality and diverse tenant base that translates into higher occupancy levels, longer leases, higher rental income, higher yields and a greater value of long-term assets. For more information on Alexandria, please visit www.are.com.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, without limitation, statements regarding the likelihood of continued investment activity by the Alexandria Venture Investments platform and the potential impacts of such investments on that of Alexandria company, the companies in which it invests, current and future health challenges, health care costs and the broader sectors of life sciences, agribusiness, climate change and technology. These forward-looking statements are based on the Company’s current intention, beliefs or expectations, but forward-looking statements are not guaranteed to occur and may not occur. Actual results may differ materially from those contained or implied in the Company’s forward-looking statements due to various factors, including, without limitation, the risks and uncertainties detailed in its documents filed with the Securities and Exchange Commission. All forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update such information. For more information on the risks and uncertainties that could cause actual results to differ materially from those anticipated in the Company’s forward-looking statements, and the risks and uncertainties regarding the Company’s business in general, please refer to documents filed by the Company with the Securities and Exchange Commission. including its most recent annual report on Form 10-K and any quarterly reports subsequently filed on Form 10-Q.

CONTACT: Sara kabakoff, Vice-President – Communications, (626) 788–5578, [email protected]

Cision

View original content: https://www.prnewswire.com/news-releases/alexandria-venture-investments-achieves-fifth-consecutive-annual-1-most-active-corporate-investor-in-biopharma-301457614.html

SOURCE Alexandria Real Estate Equities, Inc.

Share.

Comments are closed.